Viewing Study NCT06166667


Ignite Creation Date: 2025-12-25 @ 12:37 AM
Ignite Modification Date: 2025-12-25 @ 10:47 PM
Study NCT ID: NCT06166667
Status: COMPLETED
Last Update Posted: 2025-05-16
First Post: 2023-05-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Effect of Fecal Capsule on Chronic Kidney Disease (CKD)
Sponsor: Shanxi Provincial People's Hospital
Organization:

Study Overview

Official Title: Effect of Fecal Capsule on Chronic Kidney Disease (CKD)
Status: COMPLETED
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: By collecting blood, urine and stool samples before and after oral Enterobacteriaceae capsule (FMT) from CKD subjects, we investigated the role and related mechanisms of gut microecology in the development of CKD using a combination of metagenomic sequencing, metabolomic analysis and flow cytometry.
Detailed Description: Patients involved in the trial received 16 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: